Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Psychiatric Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HTR1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Cell Line Tool | HTR1A Lentivirus Premade Particles (Full-length ORF) for stable cell line construction. Sequence Verified in HEK293. Preserves native 7-TM conformation and glycosylation. | View HTR1A Products |
| Functional Antigen | HTR1A Membrane Preparation (>95% purity, Endotoxin <1EU/ug) for radioligand binding and functional assays. Also available: ECD-Fc Mutant Protein. | View HTR1A Products |
| Reference Standard | HTR1A Agonist Reference Panel (Buspirone, 8-OH-DPAT) for assay calibration. | View HTR1A Products |
| Gene Delivery | HTR1A Promise-ORF Lentivirus for rapid stable cell line construction. | View HTR1A Products |
| Benchmark Ab | Anti-HTR1A recombinant positive control (sequence verified). | View HTR1A Products |
| Validator | HTR1A siRNA Set for knockdown verification and specificity controls. | View HTR1A Products |
| Related Target A | HTR2A – Synergistic target for atypical antipsychotics and advanced antidepressants. | View HTR2A Products |
| Related Target B | HTR1B – Heterodimerization partner and critical selectivity counter-screen. | View HTR1B Products |
| Related Target C | SLC6A4 (SERT) – Key for dual-mechanism antidepressants (e.g., Vilazodone). | View SLC6A4 Products |
| Safety Counter-screen | HTR2A Lentivirus – For cardiovascular off-target profiling (5-HT2A-mediated valvulopathy risk). | View HTR2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity & Membrane Topology | Full-length HTR1A Lentivirus preserves native 7-TM structure and glycosylation. Cell-based assays are essential for functional studies. |
| Biased Signaling Discrimination (G-protein vs β-arrestin) | Cell lines support both cAMP inhibition (Gi) and β-arrestin recruitment assays for biased ligand characterization. |
| Subfamily Selectivity Screening (5-HT1A vs 5-HT1B/1D/2A) | Ortholog panel (HTR1A, HTR1B, HTR1D) available; sequence verified by mass spec. |
| Lack of Reliable Controls | Recombinant positive control benchmark antibodies and siRNA sets included. |
| Cross-species Translation (Human/Mouse/Rat/Cyno) | Multi-species ORF clones available for translational pharmacology and BBB penetration modeling. |
| False Positives in Screening | Valid sequence-verified siRNA included for cellular background specificity checks. |
Live HTR1A R&D Tracker
Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HTR1A therapeutics is intensifying, with major players shifting focus from traditional partial agonists (e.g., buspirone) to next-generation biased ligands, allosteric modulators, and polypharmacology strategies. Key players include Otsuka, Lundbeck, AbbVie (via Cerevel), and academic consortia. First-generation therapies for anxiety and depression face limitations such as receptor desensitization, delayed onset, and side effects (sexual dysfunction, emotional blunting). The next wave of R&D targets treatment-resistant depression (TRD), schizophrenia negative symptoms, neuroprotection in Alzheimer's and Parkinson's diseases, and even tumor angiogenesis inhibition via peripheral HTR1A antagonism. Advanced functional screening using reliable cell lines that preserve native GPCR conformation is critical for identifying compounds with favorable signaling bias and selectivity profiles.
Key Mutations & Genetic Variants
HTR1A is subject to several naturally occurring polymorphisms that can affect receptor function, drug response, and disease susceptibility. Key mutations documented in dbSNP include:
- rs1800041 (UniProt VAR_003446)
- rs1799920 (UniProt VAR_011826)
- rs1799921 (UniProt VAR_011827)
These variants may alter ligand binding affinity, G-protein coupling efficiency, or receptor trafficking. For mechanism-of-action studies and personalized medicine applications, TarMart offers custom mutant HTR1A lentivirus constructs (e.g., Cys101Ala, Ser/Ala phosphosite mutants) to enable precise functional characterization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Partial Agonist | Otsuka, Lundbeck, Fabre-Kramer, BMS (Vilazodone) | Major Depressive Disorder, Generalized Anxiety Disorder | GPCR Functional Assay (cAMP inhibition, GTPγS) – need full-length membrane receptor in native state |
| Biased Agonist / Allosteric Modulator | Cerevel (AbbVie), NIH/NIMH, Academic spin-offs | Treatment-Resistant Depression, PTSD, Cognition | Pathway-selective β-arrestin vs G-protein assays – need intact HTR1A stable cell lines |
| Polypharmacology (SERT + HTR1A) | AbbVie, Lundbeck, Eli Lilly | MDD with anxiety, Treatment-Resistant | Dual-target cellular screening – need HTR1A + SLC6A4 stable co-expression systems |
| Multi-target (DRD2/HTR1A) | Sumitomo Pharma, Otsuka (Brexpiprazole) | Schizophrenia, Bipolar Disorder | Selectivity Screening (HTR1A vs HTR2A/DRD2 panels) |
| Neuroprotective Agents | Biogen, Roche | Alzheimer's Disease, Parkinson's Disease | Species translation (cross-species ortholog validation) and signaling bias analysis |
Assay Strategies & TarMart Advantage
HTR1A is a prototypical Gi/o-coupled GPCR; its native conformation is essential for reliable functional data. TarMart strongly recommends cell-based assays over soluble protein approaches for drug discovery screening.
Functional Readouts:
- cAMP inhibition assay (GloSensor/TR-FRET): HTR1A activation reduces cAMP; monitor with high sensitivity.
- β-Arrestin recruitment assay (NanoBiT/PathHunter): Assess biased signaling; high β-arrestin recruitment correlates with desensitization and side effects.
- Radioligand binding ([³H]8-OH-DPAT): Determine affinity (Ki/Kd) and off-rate.
- GTPγS binding assay: Direct measure of G-protein activation.
TarMart Tools:
- Full-length HTR1A Lentivirus Premade Particles – preserve native 7-TM topology in mammalian cells.
- Pathway-specific cell lines – for parallel G-protein and β-arrestin readouts.
- Multi-species ORF clones – human, mouse, rat, cynomolgus – for translational studies.
- Mutant constructs – including phosphosite mutants for desensitization research.
- Off-target counter-screen panels – HTR1B, HTR1D, HTR2A, SLC6A4.
By integrating these tools, drug developers can efficiently profile selectivity, bias, and safety early in the pipeline.